|
Bipolar Disorder
|
0.300 |
Biomarker
|
disease |
PSYGENET |
These findings collectively suggest that CypD is a promising target for a new drug for BD.
|
20392297 |
2010 |
|
Acylcarnitines measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genome-wide association study identifies novel genetic variants contributing to variation in blood metabolite levels.
|
26068415 |
2015 |
|
Glucose measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
Human metabolic individuality in biomedical and pharmaceutical research.
|
21886157 |
2011 |
|
elevated blood glucose level
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
Human metabolic individuality in biomedical and pharmaceutical research.
|
21886157 |
2011 |
|
Serum albumin measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
A genome-wide perspective of genetic variation in human metabolism.
|
20037589 |
2010 |
|
Alzheimer's Disease
|
0.080 |
Biomarker
|
disease |
BEFREE |
Moreover, the ablation of CypD also attenuates OSCP/Aβ interaction in AD mice.
|
30266287 |
2019 |
|
Alzheimer's Disease
|
0.080 |
Biomarker
|
disease |
BEFREE |
It has been hypothesized that 17β-HSD10 interacts with cypD preventing it from opening mitochondrial permeability transition pores and that its regulation during AD may be affected by the accumulation of Aβ.
|
31723183 |
2019 |
|
Alzheimer's Disease
|
0.080 |
AlteredExpression
|
disease |
BEFREE |
Similarly, levels of cyclophilin 40 (CyP40) are reduced in the aged brain and further repressed in AD.
|
29311797 |
2017 |
|
Alzheimer's Disease
|
0.080 |
Biomarker
|
disease |
BEFREE |
In addition, in view of CypD and F1FO ATP synthase alterations seen in AD brains, the results further suggest that CypD-mediated F1FO ATP synthase deregulation is a shared mechanism linking mitochondrial deficits in brain aging and AD.
|
27834780 |
2017 |
|
Alzheimer's Disease
|
0.080 |
Biomarker
|
disease |
BEFREE |
Several recent studies have found that CypD promotes the formation of the mPTP upon binding to β amyloid (Aβ) peptides inside brain mitochondria, suggesting that neuronal CypD has a potential to be a promising therapeutic target for Alzheimer's disease (AD).
|
28913661 |
2017 |
|
Alzheimer's Disease
|
0.080 |
Biomarker
|
disease |
BEFREE |
We therefore set out to perform a proof of concept study to determine whether anesthesia and surgery can have different effects in male and female AD transgenic (Tg) mice, and in female AD Tg plus Cyclophilin D knockout (CypD KO) mice.
|
28269788 |
2017 |
|
Alzheimer's Disease
|
0.080 |
Biomarker
|
disease |
BEFREE |
These data demonstrate that abrogation of CypD results in persistent life-long protection against Aβ toxicity in an Alzheimer's disease mouse model, thereby suggesting that blockade of CypD may be of benefit for Alzheimer disease treatment.
|
19362755 |
2011 |
|
Alzheimer's Disease
|
0.080 |
Biomarker
|
disease |
LHGDN |
Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease.
|
18806802 |
2008 |
|
Breast Carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Coupling of low RRM2B and high CypD expression is associated with aggressive manifestations of breast cancer.
|
30662615 |
2018 |
|
Breast Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Oroxylin A induces dissociation of hexokinase II from the mitochondria and inhibits glycolysis by SIRT3-mediated deacetylation of cyclophilin D in breast carcinoma.
|
23598413 |
2013 |
|
Breast Carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
We have recently shown that CyP40 and FKBP52 mRNA's are differentially elevated in breast carcinomas compared with normal breast tissue.
|
11374893 |
2001 |
|
Breast Carcinoma
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
Allelic loss was detected in 30% of breast carcinomas from patients heterozygous for the CyP40 marker.
|
11216911 |
2001 |
|
Kidney Failure, Acute
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Mitochondrial translocation of PPARα, its binding to cyclophilin D, and sequestration led to inhibition of its nuclear translocation and transcription of PPARα-regulated fatty acid oxidation genes during cisplatin-induced acute kidney injury.
|
31733829 |
2020 |
|
Diabetes
|
0.030 |
Biomarker
|
disease |
BEFREE |
We tested the hypothesis of whether NMDA-R1 mediates Ca<sup>2+</sup> influx causing CypD activation and MPTP opening leading to oxidative stress and renal injury in diabetes.
|
31039005 |
2019 |
|
Diabetes Mellitus
|
0.030 |
Biomarker
|
group |
BEFREE |
We tested the hypothesis of whether NMDA-R1 mediates Ca<sup>2+</sup> influx causing CypD activation and MPTP opening leading to oxidative stress and renal injury in diabetes.
|
31039005 |
2019 |
|
Kidney Failure, Acute
|
0.030 |
Biomarker
|
disease |
BEFREE |
p53-cyclophilin D mediates renal tubular cell apoptosis in ischemia-reperfusion-induced acute kidney injury.
|
31339772 |
2019 |
|
Kidney Failure, Acute
|
0.030 |
Biomarker
|
disease |
BEFREE |
Cyclophilin D (CypD) is an important component in mitochondrial-dependent tubular cell death in acute kidney injury.
|
29230844 |
2018 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
The opening of the mitochondrial permeability transition pore (PTP), which is regulated by the matrix protein cyclophilin D (CypD), plays a key role in the pathophysiology of post-cardiac arrest (CA) syndrome.
|
28492973 |
2017 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
The mitochondrial pepdidyl-prolyl isomerase cyclophilin D (CypD) is an important regulator of the mitochondrial permeability transition and a key player in mitochondria physiology; however, its role in cancer is still unclear.
|
26973251 |
2016 |
|
Diabetes
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Brains from mice with STZ-induced diabetes revealed a significant increase of cyclophilin D (CypD) expression, reduced respiratory function, and decreased hippocampal long-term potentiation (LTP); these animals had impaired spatial learning and memory.
|
25096625 |
2015 |